Grants Awarded

2009

BioMedical Research Models Inc (BRM) awarded a $2.5 Million NIH grant

Kejian Yang Ph.D., a research director at BioMedical Research Models Inc has been awarded a three year grant from the National Institutes of Allergy and Infectious Disease (NIAID) totaling $2,563,532. The objectives of this grant are to extend studies and develop a vaccination strategy for genital herpes. Read more

2006

Biomedical Research Models has received a fundable priority score of 155 for a phase 1 SBIR grant totaling $590,536, entitled "A mucosal vaccine for HSV-2".

The project will be funded for a 2 year period of performance beginning 3/1/06. The principal investigator on the grant will be Rebecca S. Tirabassi, Ph.D. Research Director and expert on human cytomegalovirus.

Biomedical Research Models Inc. signed a five year contract with the National Institutes of Diabetes Digestive and Kidney Diseases (NIDDK) totaling $4,889,031.

The objectives of this contract are to assist NIDDK in development of potential new therapies for the prevention of Type 1 diabetes. Read more

2004

Biomedical Research Models has been awarded a phase 1 SBIR grant totaling $1,000,000, entitled "Neurogenic compounds for treating diabetic complications".

The project is funded for a 2 year period of performance which began 9/30/04 and ends 8/31/06. The principal investigator on the grant is Rebecca S. Tirabassi, Ph.D. Research Director and expert on human cytomegalovirus.

Biomedical Research Models has been awarded a phase 1 SBIR grant totaling $393,589, entitled "In-stent Stenosis model in type 2 diabetic rats".

The project is to develop and validate a novel in-stent stenosis animal model system to accelerate advances in vascular disease therapeutics and device testing. Funding is for a 2 year period of performance which began 6/01/04 and ends 5/31/06. The principal investigator on the grant is Tiangen Wu, M.D. Research Director.

Biomedical Research Models has been awarded a phase 1 STTR grant totaling $223,141, entitled "Engineering Myoblasts for Transplantation".

The 1.5 year project ran from July 1, 2004 - December 31, 2005. The principal investigator on the grant, Edward H. Kislauskis, Ph.D., is the Vice President and co-founder of BRM, Inc.

Biomedical Research Models has been awarded a phase 1 SBIR grant totaling $319,762, entitled "New model for virus induced autoimmunity".

The objective of the program is to study the process of viral induction of autoimmune diabetes. Funding is for a 1.5 year period of performance which began 701/04 and ends 12/31/05. The principal investigator on the grant is Dennis L. Guberski, M.S., President and founder of BRM.

2001

Biomedical Research Models Inc has been awarded a Phase 1 SBIR grant totaling $342.704 to characterize the BBZDR rat new model of Type 2 Diabetes.

The project is funded for a two-year period of performance, which began on June 1, 2001. The Principal Investigator on the grant is Dennis L. Guberski, the president and founder of BRM Inc.

2000

Biomedical Research Models Inc has been awarded a Phase 1 SBIR grant totaling $123,148 to develop an antibody directed at Notch-1 receptors on stem cells.

The project is funded for a six-month period of performance, which began on September 14, 2000. The Principal Investigator on the grant is Edward H. Kislauskis Ph.D. the Vice president and co-founder of BRM Inc.